The Contraceptive Patch From Zydus Lifesciences Has Received Final Usfda Approval

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

The contraceptive patch from Zydus Lifesciences has received final USFDA approval

ri-calendar-2-lineSep 18, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

The US Food and Drug Administration (USFDA) gave its final approval to Zydus Lifesciences Ltd.'s Norelgestromin and Ethinyl Estradiol Transdermal System on Friday. It is a skin patch that contains a mixture of hormone medications and is used to prevent pregnancy.

 

With its most recent approval, the pharmaceutical group now has 380 approvals and over 444 ANDAs filed for the fiscal years 2003–2004, according to the company.

 

According to Zydus Lifesciences, the Norelgestromin and Ethinyl Estradiol Transdermal System is the third hormonal transdermal patch approved by the USFDA from its generics portfolio.

 

The company's formulation manufacturing plant in Moraiya, Ahmedabad, Gujarat, will produce the contraceptive patch.

 

Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day, had sales of $330 million per year in the US, according to IQVIA MAT data from July 2023.

 

On September 13, Zydus also announced that it had received the EIR report from the USFDA with no observations for the injectables production plant at the Changodar, Ahmedabad-based Zydus Biotech Park.

 

The USFDA inspected from June 5 to June 13, 2023.

 

Erythromycin Tablets USP 250 mg and 500 mg, used to prevent and treat infections in many different sections of the body, were also given final FDA approval this month, according to Zydus.

 

In the US, annual sales of erythromycin tablets, USP, 250 mg and 500 mg, were $23 million.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions